Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios

Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:International urology and nephrology Ročník 51; číslo 12; s. 2107 - 2117
Hlavní autori: Cetin, Bulent, Kosar, Alim
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Dordrecht Springer Netherlands 01.12.2019
Springer Nature B.V
Predmet:
Aged
Carcinoma, Renal Cell - therapy
Clear cell-type renal cell carcinoma
Clinical trials
Clinical Trials as Topic
Decision making
Drug development
Female
Humans
Immune checkpoint inhibitors
Immunotherapy
Kidney cancer
Kidney Neoplasms - therapy
Male
Medicine
Medicine & Public Health
Metastases
Metastasis
Middle Aged
Molecular Targeted Therapy
Monoclonal antibodies
Nephrology
Patients
Risk groups
Targeted cancer therapy
Tyrosine
Urology
Urology - Review
Vascular endothelial growth factor
Metastatic renal cell carcinoma
Immunotherapy
Tyrosine kinase inhibitors
ISSN:0301-1623, 1573-2584, 1573-2584
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC. Materials and methods Between 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC. Results Immunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC. Conclusion In renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Case Study-2
ObjectType-Review-5
ObjectType-Feature-3
content type line 23
ObjectType-Article-4
ObjectType-Report-1
ISSN:0301-1623
1573-2584
1573-2584
DOI:10.1007/s11255-019-02264-5